Maastricht UMC+ account plan
Patient-centered healthcare services
At a glance
Maastricht UMC+ is the Dutch academic medical centre of azM and Maastricht University: EUR 1,230 mln revenue and 7,125 employees in 2025.
Maastricht UMC+ is the partnership between the academic hospital azM (academisch ziekenhuis Maastricht) and the Faculty of Health, Medicine and Life Sciences of Maastricht University. It provides top-referral and top-clinical care, research, education and valorisation, plus basic hospital care for Maastricht and its surroundings, and is one of the largest employers in South Limburg. In 2025 consolidated revenue was EUR 1,230 mln (EUR 1,171 mln in 2024) and the consolidated result fell to EUR 6.5 mln from EUR 22.0 mln. It had 7,125 employees (5,412 FTE), 546 beds and 16 operating theatres, with 24,048 admissions. The azM is a public-law entity governed by an Executive Board chaired by Helen Mertens and a Supervisory Board chaired by Roger Dassen.
Business units
azM academic hospital
about 85% of 2025 consolidated revenue (EUR 1,044.1 mln)The core hospital, organised in eight centres for patient care, 24 medical departments and five expertise units, delivering top-referral care for complex and rare conditions. Its 2025 operating result was EUR -3.1 mln (EUR +15.8 mln in 2024) as costs of EUR 1,047.1 mln outpaced revenue.
FHML research institutes
The Maastricht University faculty partner, not consolidated in the azM figures, with nine thematic research institutes including CAPHRI, CARIM, GROW, NUTRIM and M4I. In 2025 it launched the Climate HEALTH institute on climate and health.
St. Jans Gasthuis Weert
A wholly owned independent regional hospital used to deliver secondary care at the right place, freeing room in Maastricht for complex academic care. Joint dermatology and rheumatology groups started in Weert in 2025.
Annadal Kliniek
A wholly owned independent treatment centre that receives less complex care moved out of the academic hospital under the Briljant programme.
Clinical Trial Center Maastricht
A wholly owned company that supports researchers in setting up and running clinical studies; completing several profitable projects drove most of the EUR 3.8 mln improvement in participations' result.
Other participations and foundations
Stakes including CIRO+ (51%), Maastro Protonentherapie (20%), Maastricht Instruments (40%) and Maastricht Health Campus, plus foundations such as Health Foundation Limburg. Together the participations contributed EUR 9.1 mln to the 2025 single-entity result.
Strategic priorities
- National centre for prevention and vitality
- Under the strategy Gezond Leven 2025 - nader ingekleurd, MUMC+ aims to become the national knowledge and expertise centre for prevention and vitality, with the ambition to be the national centre for prevention, lifestyle and vitality in 2030.
- Stronger academic profile (Briljant)
- The Briljant programme, started in 2025, aims to attract more academic patients and move non-academic care to SJG Weert and Annadal Kliniek.
- Care of the future
- A strategic programme on data-driven work, digitalisation, AI and hybrid care such as 24/7 monitoring on wards and home monitoring; the strategy is being renewed in 2026 around sustainability, climate, data, AI, quality of life and vitality.
- Culture and social safety
- After a BCG culture study in which over 4,000 staff took part, the programme Veiligheid, duidelijkheid en vertrouwen started and an improvement plan has been carried out since early 2026.
- Sustainability targets
- 55% CO2 reduction by 2030 versus 2015 and 95% by 2050, and halving primary raw-material use by 2030.
- Cooperation with Maastricht University
- Employee councils voted against administrative integration, so the integration plan is being reconsidered in 2026 and the CEO is looking for another governance model.
Investments and deals
- Building programme 2026-2040
- A new entrance building and thorough renovation of the bed tower, wards and outpatient clinics; the CEO puts the total at EUR 600 mln, the Supervisory Board at EUR 500 mln in the coming years, and the annual report at about EUR 40 mln a year. Work on the entrance building starts in 2026 and a EUR 200 mln financing request for 2027-2029 is being prepared.
- New ERP system
- A new ERP for procurement, logistics and finance was awarded to Delaware/SAP in autumn 2025, with implementation from early 2026 to H1 2027 (indicative EUR 12 mln).
- Epic EHR and ICT
- The Epic EHR has been live since November 2024; ICT investment runs at about EUR 7.3 mln a year for storage, telecom and network.
- Medical equipment
- About EUR 13 mln a year, mostly replacements; two Da Vinci 5 robots and a Hugo robot system followed in 2026.
Challenges and risks
- Cuts to academic funding
- Planned cuts to the BBAZ academic-care contribution and specialist-training funds from 2029 are a major financial threat, and measures are already needed in 2026.
- Thin financial result
- Costs rose EUR 65 mln against EUR 46.2 mln more revenue in 2025, driven by collective-agreement effects, more FTE, medicine costs and Epic licence and capital charges.
- Staff shortages
- Staff shortages and organisational agility are a top strategic risk; there were 498 vacancies during 2025 and scarce professions remain hard to fill.
- Information and data security
- Availability, integrity, confidentiality and sovereignty of data are a strategic risk, including less dependence on big tech.
- Rising care demand
- Rising care demand and dilution of the academic profile are among the six strategic top risks re-assessed in 2025.
What leadership says
“We knew that the relatively high results of the years before were not structural. We did not count ourselves rich on them.”
“Despite the still tight labour market, we currently succeed faster in filling our open vacancies.”
“At the same time everyone recognises the need for far-reaching cooperation, to seize growth opportunities and stand up to threats. Together we can increase our contribution to society; separately we are more vulnerable.”
Where a supplier can help
- ERP implementation support
- Tied to the Delaware/SAP ERP rollout from early 2026 to H1 2027: procurement, logistics and finance process, data migration and training partners.
- Construction and renovation supply
- Tied to the 2026-2040 building programme: contractors, medical furnishing and equipment suppliers for the entrance building, bed tower and outpatient clinics.
- Cost and result improvement
- Tied to the thin financial result and the funding cuts: suppliers that lower medicine, licence or operating costs fit the result-improvement initiatives built into 2026 budgets.
- Recruitment and workforce tools
- Tied to the staff-shortage risk: recruitment, scheduling and retention solutions for scarce professions.
- Hybrid care and data security
- Tied to the care-of-the-future programme and the data-security risk: remote monitoring, AI and sovereign data solutions.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Maastricht UMC+?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Jaarverslag Maastricht UMC+ 2025 (annual report of the academisch ziekenhuis Maastricht)
- Maastricht UMC+ is the partnership between the academic hospital azM (academisch ziekenhuis Maastricht, the reporting legal entity) and the Faculty of Health, Medicine and Life Sciences (FHML) of Maastricht University; it provides top-referral and top-clinical care, research, education and valorisation, plus basic hospital care for Maastricht and its surroundings.
- 2025 scale: consolidated revenue of EUR 1,230 mln (EUR 1,171 mln in 2024), 7,125 employees / 5,412 FTE, 546 beds, 16 operating theatres, 24,048 admissions, 123,234 first consultations and 33,561 emergency consultations.
- Consolidated result fell to EUR 6.5 mln (EUR 22.0 mln in 2024); the azM itself lost EUR 3.1 mln while participations earned EUR 9.1 mln. Costs rose EUR 65 mln against EUR 46.2 mln more revenue, driven by collective-agreement effects, more FTE, medicine costs and Epic licence and capital charges.
- Strategy "Gezond Leven 2025 - nader ingekleurd": become THE national knowledge and expertise centre for prevention and vitality, and strengthen the academic profile; the Briljant programme (started 2025) aims to attract more academic patients and move non-academic care to subsidiaries Annadal Kliniek and SJG Weert. The strategy is being renewed in 2026.
- IT: Epic EHR live since November 2024; a new ERP (procurement, logistics, finance) was awarded to Delaware/SAP in autumn 2025, implementation from early 2026 to H1 2027 (indicative EUR 12 mln). ICT investment about EUR 7.3 mln a year, medical equipment about EUR 13 mln a year; two Da Vinci 5 robots and one Hugo robot.
- Building programme 2026-2040: new entrance building and renovation of wards and outpatient clinics, about EUR 40 mln a year of building investment; a EUR 200 mln financing request for 2027-2029 is being prepared. Solvency 33.6%, DSCR 1.66, equity EUR 429.4 mln.
- Main risks: staff shortages and organisational agility, rising care demand, dilution of the academic profile, information and data security (including sovereignty and less dependence on "big tech"), prevention coordination, and steering of strategic networks; planned cuts to the BBAZ academic-care contribution and specialist-training funds from 2029 are a major financial threat.
- Governance: CEO Helen Mertens; CFO Gabriel Zwart left on 17 December 2025 after ten years (Veronique Thoelen acting CFO); Jos Maessen added as titular board member; Supervisory Board chaired by Roger Dassen. Employee councils voted against administrative integration with Maastricht University, so the integration plan is being reconsidered in 2026.
- A BCG culture study (over 4,000 staff took part) found no new structural cases of social unsafety but flagged leadership, communication, inclusion and informal networks; an action plan was shared in February 2026.
- Verslag van de Raad van Toezicht 2025 (Supervisory Board report, azM)
- Report of the Supervisory Board (Raad van Toezicht) of the azM for 2025, signed by chair Roger Dassen (also CFO and board member of ASML).
- Board composition unchanged: Roger Dassen (chair), Anne Marie de Smet (vice-chair), Thomas van Elzakker, Carla Moonen, Jan-Paul Rutten; seven meetings in 2025.
- Executive Board changes: Jos Maessen added as titular board member from 1 January 2025; CFO Gabriel Zwart stepped down in December 2025 after 10 years; recruitment of two new Executive Board members started at the end of December.
- Social safety was the top theme: the board backed the organisation-wide external culture study and the programme 'Veiligheid, duidelijkheid en vertrouwen'.
- Strategic cooperation with Maastricht University is called of great importance, but employee councils of both organisations gave negative advice on administrative integration.
- The board approved the 2024 accounts in April 2025 and the 2026 budget in December, with special attention to result-improvement initiatives; it set the 2025 result at EUR 6.5 mln.
- EUR 500 mln will be invested in renovations and renewal in the coming years; work on the new entrance building starts in 2026.
- Also discussed: the Epic EHR, the ERP tender, strategic risks, the Qualicor diamond accreditation and the clients' council's binding nomination right for a supervisory seat.
- Financieel mager jaar voor Maastricht UMC+ (CEO Helen Mertens on the 2025 annual report)
- Helen Mertens, chair of the Executive Board, comments on the 2025 annual report (news release of 26 May 2026).
- 2025 result was a slightly positive EUR 6.5 mln versus EUR 22 mln in 2024, mainly because of heavy investment in staff and ICT; 2024 had been flattered by incidental income such as final settlements with health insurers.
- Mertens says the more modest 2025 result was foreseen and that the high earlier results were known not to be structural.
- Results will stay under pressure: the coalition agreement cuts the BBAZ academic-care contribution and subsidies for medical specialist training, and new-build and renovation weigh on results.
- MUMC+ is investing EUR 600 mln in building works that start in 2026 and run to 2040: a new entrance building and a thorough renovation of the bed tower and outpatient clinics, more than 35 years after the hospital opened.
- A culture improvement plan, drawn up with staff after last year's external study, has been carried out since early 2026; vacancies are being filled faster despite a tight labour market.
- Lack of support from most employee councils for administrative integration with Maastricht University is a setback; Mertens keeps looking for a governance model that secures the cooperation.
Questions about Maastricht UMC+
What is Maastricht UMC+?
It is the partnership between the academic hospital azM and the Faculty of Health, Medicine and Life Sciences of Maastricht University, providing top-referral care, research, education and basic hospital care for the Maastricht region.
What is Maastricht UMC+'s revenue?
Consolidated revenue was EUR 1,230 mln in 2025 (EUR 1,171 mln in 2024), with a consolidated result of EUR 6.5 mln.
How many people work at Maastricht UMC+?
7,125 employees, or 5,412 FTE, at the end of 2025.
Who leads Maastricht UMC+?
Helen Mertens chairs the Executive Board, with Veronique Thoelen as acting CFO after Gabriel Zwart left in December 2025; Roger Dassen chairs the Supervisory Board.
What is Maastricht UMC+'s strategy?
To become the national knowledge and expertise centre for prevention and vitality and strengthen its academic profile, notably by moving non-academic care to its subsidiaries under the Briljant programme.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)